|
|
Volumn 18, Issue 17, 2012, Pages 4491-4497
|
|
The European Medicines Agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: Summary of the scientific assessment of the committee for medicinal products for human use
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CAPECITABINE;
ERIBULIN;
ALOPECIA;
ANTINEOPLASTIC ACTIVITY;
APOPTOSIS;
ARTICLE;
ASTHENIA;
BREAST CANCER;
BREAST METASTASIS;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CELL CYCLE ARREST;
CELL CYCLE G2 PHASE;
CELL CYCLE M PHASE;
CHEMOTHERAPY INDUCED EMESIS;
CONSTIPATION;
CONTINUOUS INFUSION;
DRUG CLEARANCE;
DRUG DISTRIBUTION;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG FATALITY;
DRUG FEVER;
DRUG INDICATION;
DRUG MEGADOSE;
DRUG METABOLISM;
DRUG SAFETY;
DRUG STRUCTURE;
DYSPNEA;
EUROPEAN UNION;
FATIGUE;
FEBRILE NEUTROPENIA;
HUMAN;
LEUKOPENIA;
LIVER DYSFUNCTION;
MICROTUBULE;
MITOSIS SPINDLE;
MOTOR NEUROPATHY;
MULTIPLE CYCLE TREATMENT;
NAUSEA;
NEUTROPENIA;
NONHUMAN;
OVERALL SURVIVAL;
PERIPHERAL NEUROPATHY;
PLEURA EFFUSION;
PRIORITY JOURNAL;
QT PROLONGATION;
RECOMMENDED DRUG DOSE;
RISK BENEFIT ANALYSIS;
SENSORY NEUROPATHY;
SURVIVAL TIME;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CLINICAL TRIALS, PHASE III AS TOPIC;
EUROPE;
FEMALE;
FURANS;
HEALTH SYSTEMS AGENCIES;
HUMANS;
KAPLAN-MEIER ESTIMATE;
KETONES;
NEOPLASM STAGING;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RISK ASSESSMENT;
TREATMENT OUTCOME;
|
|
EID: 84865711913
PISSN: 10780432
EISSN: 15573265
Source Type: Journal
DOI: 10.1158/1078-0432.CCR-11-3075 Document Type: Article |
|
Times cited : (31)
|
|
References (5)
|
